JP2022536854A5 - - Google Patents

Info

Publication number
JP2022536854A5
JP2022536854A5 JP2021575320A JP2021575320A JP2022536854A5 JP 2022536854 A5 JP2022536854 A5 JP 2022536854A5 JP 2021575320 A JP2021575320 A JP 2021575320A JP 2021575320 A JP2021575320 A JP 2021575320A JP 2022536854 A5 JP2022536854 A5 JP 2022536854A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
patient
inhibitor
cdk4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021575320A
Other languages
English (en)
Japanese (ja)
Other versions
JP7812232B2 (ja
JP2022536854A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/038557 external-priority patent/WO2020257536A1/en
Publication of JP2022536854A publication Critical patent/JP2022536854A/ja
Publication of JP2022536854A5 publication Critical patent/JP2022536854A5/ja
Application granted granted Critical
Publication of JP7812232B2 publication Critical patent/JP7812232B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021575320A 2019-06-18 2020-06-18 癌患者における抗腫瘍免疫の増強のための患者選択 Active JP7812232B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962863153P 2019-06-18 2019-06-18
US62/863,153 2019-06-18
US201962907375P 2019-09-27 2019-09-27
US62/907,375 2019-09-27
PCT/US2020/038557 WO2020257536A1 (en) 2019-06-18 2020-06-18 Patient selection for enhancement of anti-tumor immunity in cancer patients

Publications (3)

Publication Number Publication Date
JP2022536854A JP2022536854A (ja) 2022-08-19
JP2022536854A5 true JP2022536854A5 (cg-RX-API-DMAC7.html) 2023-06-27
JP7812232B2 JP7812232B2 (ja) 2026-02-09

Family

ID=74040931

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021575320A Active JP7812232B2 (ja) 2019-06-18 2020-06-18 癌患者における抗腫瘍免疫の増強のための患者選択

Country Status (9)

Country Link
US (1) US20220175787A1 (cg-RX-API-DMAC7.html)
EP (1) EP3986410A4 (cg-RX-API-DMAC7.html)
JP (1) JP7812232B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220024540A (cg-RX-API-DMAC7.html)
CN (1) CN114222577A (cg-RX-API-DMAC7.html)
AU (1) AU2020296087A1 (cg-RX-API-DMAC7.html)
CA (1) CA3143339A1 (cg-RX-API-DMAC7.html)
TW (1) TW202114684A (cg-RX-API-DMAC7.html)
WO (1) WO2020257536A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6430483B2 (ja) * 2013-03-15 2018-11-28 ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. 化学療法の間の正常細胞の一時的な保護
IL317919A (en) 2016-12-05 2025-02-01 G1 Therapeutics Inc Preservation of immune response during chemotherapy regimens
JP7853532B2 (ja) 2020-05-19 2026-04-30 ファーマコスモス ホールディング エー/エス 医学的障害を治療するためのサイクリン依存性キナーゼ阻害化合物
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
US20240285634A1 (en) * 2021-06-10 2024-08-29 Onquality Pharmaceuticals China Ltd. Compound and method for treating chemotherapy-associated gastrointestinal side effects
CA3223467A1 (en) * 2021-07-01 2023-01-05 Andrew BEELEN Combination treatments in patients with advanced and/or metastatic trop-2 overexpressed cancers
US20250003986A1 (en) * 2021-10-14 2025-01-02 Wisconsin Alumni Research Foundation K17 as a biomarker for tumor response to immunotherapy
CN115019880B (zh) * 2022-05-05 2024-01-09 中山大学附属第一医院 一种肝癌预后模型及其构建方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102186969B1 (ko) 2010-10-25 2020-12-04 쥐원 쎄라퓨틱스, 인크. Cdk 억제제
JP6430483B2 (ja) * 2013-03-15 2018-11-28 ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. 化学療法の間の正常細胞の一時的な保護
US10551379B2 (en) 2013-03-15 2020-02-04 President And Fellows Of Harvard College Methods and compositions for improving detection and/or capture of a target entity
US20160220569A1 (en) * 2015-02-03 2016-08-04 G1 Therapeutics, Inc. CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy
US11865176B2 (en) * 2016-11-08 2024-01-09 Dana-Farber Cancer Institute, Inc. Compositions and methods of modulating anti-tumor immunity
IL317919A (en) * 2016-12-05 2025-02-01 G1 Therapeutics Inc Preservation of immune response during chemotherapy regimens
EP3585389A4 (en) * 2017-02-22 2020-12-23 G1 Therapeutics, Inc. EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS
US20200377599A1 (en) * 2017-11-30 2020-12-03 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating cancer
US10122265B1 (en) 2018-01-03 2018-11-06 Intel Corporation Reducing electromagnetic interference in switching regulators
WO2023034336A2 (en) * 2021-08-30 2023-03-09 G1 Therapeutics, Inc. Improved treatments for advanced/metastatic cancers with checkpoint inhibitor resistance or resistance susceptibility

Similar Documents

Publication Publication Date Title
Park et al. Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer
Sen et al. Combination treatment of the oral CHK1 inhibitor, SRA737, and low-dose gemcitabine enhances the effect of programmed death ligand 1 blockade by modulating the immune microenvironment in SCLC
EP3903828A1 (en) Combination of antibody-drug conjugate and kinase inhibitor
JP7564122B2 (ja) 光免疫療法のための方法および関連バイオマーカー
Wakasaki et al. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma
Ma et al. Enhanced immunotherapy of SM5-1 in hepatocellular carcinoma by conjugating with gold nanoparticles and its in vivo bioluminescence tomographic evaluation
Barot et al. Recent advancement in targeted therapy and role of emerging technologies to treat cancer
JP2015514113A (ja) 単一特異性および二重特異性抗igf−1rおよび抗erbb3抗体の用法および用量
RU2016141385A (ru) Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
US12213958B2 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
CN114340679A (zh) 用于治疗对pd-1/pd-l1信号传导抑制剂无应答的癌症的方法和药物
KR20240029045A (ko) 진행성 및/또는 전이성 Trop-2 과다발현 암을 갖는 환자에서의 조합 치료
Qin et al. CD19-targeted HSP90 inhibitor nanoparticle combined with TKIs reduces tumor burden and enhances T-cell immunity in murine B-cell malignancies
Candelaria et al. Lack in Efficacy for Imatinib Mesylate as Second-Line Treatment of Recurrent or Metastatic Cervical Cancer Expressing Platelet-Derived Growth Factor Receptor a
JP2021073203A (ja) Her2陽性転移性乳癌の治療方法
CA3225489A1 (en) Compositions and methods for treatment of cancer
JP7829491B2 (ja) 6-チオ-dG、チェックポイント阻害剤および放射線療法を使用するがんの逐次処置
US20250368714A1 (en) Treatment of cancer
Thomas et al. Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer: GFPC 99-01 study (Groupe français de pneumo-cancérologie)
Piatek et al. Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors
WO2024183818A1 (zh) 抗cd20抗体药物偶联物在制备治疗非霍奇金淋巴瘤的药物中的用途
JP2024516970A5 (cg-RX-API-DMAC7.html)
Mu et al. A biomimetic nanodisc system selectively activates type I interferons by nonclassical STING pathway for cancer immunotherapy
Solernó et al. Drug Repurposing of β-blocker Propranolol in Osteosarcoma: Preclinical Antitumor Efficacy Alone or in Combination with Chemotherapy.
CN118804760A (zh) 癌症的治疗